[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"esophagus-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:esophagus-cancer":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,32,0,25,[9,45,66,88,113,133,164,189,216,237,264,320,343,441,468,503,524,547,568,589,609,633,657,685,712],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100499240","individualized-dose-escalation-of-5-fu-for-gastrointestinal-cancer-100499240",false,"NCT05780684","Individualized Dose Escalation of 5-FU for Gastrointestinal Cancer","Adaptive, Individualized Dose Escalation of Fluorouracil-Based Chemotherapy for Gastrointestinal Cancer: Pilot Study of the FOX Regimen","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of metastatic or locally advanced\u002Finoperable colorectal cancer or non-colorectal gastrointestinal cancer (including cancers of the stomach, esophagus, appendix, small bowel, and ampulla)\n* Clinically appropriate staging imaging of the chest, abdomen, and pelvis performed within 30 days prior to registration\n* ECOG Performance Status: 0-1\n\nExclusion Criteria:\n\n* Any prior receipt of oxaliplatin or fluoropyrimidine chemotherapy (other than radiation-sensitizing fluoropyrimidine chemotherapy)\n* Prior receipt of systemic chemotherapy in the 6 months prior to Day 1 of Cycle 1 of FOX (other than radiation-sensitizing chemotherapy)\n* Known mismatch repair deficiency or microsatellite instability-high disease\n* Known dihydropyrimidine dehydrogenase (DPD) deficiency, as identified by clinically indicated screening\n* Any confirmed second malignancy that is likely to require systemic therapy during the course of the six-month study period, in the opinion of the enrolling investigator\n* Any of the following baseline laboratory abnormalities:\n\n  * Absolute neutrophil count (ANC) \\\u003C 2,500\u002Fmm3\n  * Platelet count \\\u003C 100,000\u002Fmm3\n  * Hemoglobin \\\u003C 9 g\u002FdL\n  * Creatinine \\> 1.5 x ULN\n  * Total bilirubin \\> 1.5 x ULN\n  * AST\u002FALT \\> 5 x ULN\n  * Patients who are unable to provide informed consent\n  * Patients who are pregnant or breastfeeding\n  * Patients who are incarcerated, homeless, or have active substance use disorders","ALL","18 Years",{"count":20,"type":21},36,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a single-arm clinical trial to evaluate the feasibility of a chemotherapy regimen using adaptive, individualized dose escalation of 5-FU chemotherapy for patients who have good tolerance of the initial dose. Study participants will also receive oxaliplatin chemotherapy together with 5-FU, at standard doses. The goal of the study is to examine the feasibility and effectiveness of this approach, using individualized dose escalation of 5-FU in patients who do not have serious side effects at lower doses.",[27,28,29,30,31],"Colorectal Cancer","Esophagus Cancer","Appendix Cancer","Small Bowel Cancer","Ampullary Cancer","RECRUITING","2026-06-18",{"date":35,"type":36},"2026-06-22","ACTUAL",{"date":38,"type":36},"2023-07-14",{"date":40,"type":21},"2027-12",{"name":42,"class":43},"Dartmouth-Hitchcock Medical Center","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":44},"100185087","proton-therapy-for-esophageal-cancer-100185087","NCT01684904","Proton Therapy for Esophageal Cancer","A Phase II Trial of Proton Chemotherapy (PCT) for Resectable Esophageal or Esophagogastric Junction Cancer","Inclusion Criteria:\n\n* Pathologically confirmed primary squamous cell or adenocarcinoma of the esophagus that involves the mid, distal or esophagogastric junction. The cancer may involve the stomach up to 5 cm.\n* Endoscopy with biopsy\n* Stage T1N102, T2-3N0-2 according to the American Joint Committee on Cancer (AJCC) 7th edition staging, based upon the following minimum diagnostic work-up:\n\nHistory\u002Fphysical examination with documentation of patient's weight within 30 days of registration\n\nChest\u002FAbdominal\u002FPelvic contrast CT within 56 days of registration\n\nWhole body PET\u002FCT within 56 days of registration\n\nEndoscopic ultrasound\n\nPatients may have regional adenopathy including para-esophageal, gastric, gastroheptaic and celiac nodes. If celiac adenopathy present, it must be ≤ 2cm.\n\nPatients with tumors at the level of the carina or above should undergo bronchoscopy to exclude fistula\n\nPulmonary function test (including routine spirometry and DLCO) within 60 days prior to registration\n\nSerum creatinine ≤ 2 x the upper limit of normal within 4 weeks of registration\n\nNa, K, BUN, Glucose within 4 weeks prior to registration\n\nCBC\u002Fdifferential within 4 weeks prior to registration with adequate bone marrow function, defined as follows:\n\n* Absolute neutrophil count (ANC) ≥ 1,500 cells\u002Fmm3\n* Platelets ≥ 100,000 cell\u002Fmm3\n* Hemoglobin ≥ 8.0 g\u002Fdl (Note: the use of transfusion or other intervention to achieve Hgb ≥ 8.0 is acceptable.)\n\nAdequate liver function, defined as total bilirubin ≤ 1.5 x upper limit of normal, AST ≤ 3 x the upper limit of normal within 4 weeks of registration\n\nAge ≥ 18\n\nZubrod performance status 0-2 within 4 weeks of registration\n\nSurgical consultation to confirm that patient will be able to undergo curative resection after completion of PCT prior to registration\n\nFor women of childbearing potential, a negative serum pregnancy test within 14 days prior to registration\n\nWomen of childbearing potential and male participants must practice adequate contraception while on study\n\nPatient must sign study specific informed consent prior to study entry\n\nExclusion Criteria:\n\nPatients with cervical esophageal carcinoma\n\nPatients with T1N0 disease and T4 disease\n\nPrior radiation for esophageal cancer or prior chest radiotherapy\n\nPrior chemotherapy for esophageal cancer\n\nEvidence of tracheoesophageal fistula or invasion into the trachea or major bronchi\n\nPrior invasive malignancy (except non-melanomatous skin cancer), unless disease free for a minimum of 2 years ( e.g. carcinoma in situ of breast, oral cavity, or cervix are permissible)\n\nPrior radiotherapy that would results in overlap of radiation fields\n\nMedical contraindications to esophagectomy\n\nPrior allergic reaction to paclitaxel or carboplatin\n\nSevere, active co-morbidity that may impact survival\n\nPregnancy, nursing women, or women of child bearing potential, and men who are sexually active and not willing\u002Fable to use medically acceptable forms of contraception\n\n\\-",{"count":53,"type":21},38,[24],"The goal of this phase II study is to investigate the feasibility, toxicity and efficacy of a regimen incorporating a proven systemic regimen, carboplatin \u002Fpaclitaxel, with conformal proton modality, followed by definitive surgery. In most combined-modality trials to date, chemotherapy regimens have included cisplatin, usually in conjunction with 5-fluorouracil.\n\nIn designing the regimen, the investigators attempt to improve on the standard cisplatin\u002F5-fluorouracil regimen in several ways. First, full-dose paclitaxel is added to the regimen. This agent has activity against advanced esophageal cancer and is also a potent radiosensitizer. Second, the substitution of carboplatin for cisplatin has resulted in reduced toxicity of various combination regimens similar to that used by CROSS trial and allows for easier administration in the outpatient setting.4 Third, for localized esophageal cancer, dose distribution patterns achievable with proton beam could potentially offer important clinical advantages relative to those achievable with x-rays (photons).19 Based on this, the investigators believe that this study should be conducted with the radiation modality that offers the best dosimetry achievable at our institution.",[28],"2026-06-03",{"date":59,"type":36},"2026-06-05",{"date":61,"type":36},"2013-02-20",{"date":63,"type":21},"2032-08",{"name":65,"class":43},"Loma Linda University",{"id":67,"slug":68,"hasResults":12,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":22,"phases":74,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":44},"100640685","phase-2-the-efficacy-and-safety-of-fosrolapitant-and-palonosetron-hydrochloride-for-injection-in-preventing-nausea-and-vomiting-caused-by-multi-cycle-immunotherapy-and-chemotherapy-in-patients-with-esophageal-cancer-and-lung-cancer-100640685","NCT07617246","The Efficacy and Safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in Preventing Nausea and Vomiting Caused by Multi-cycle Immunotherapy and Chemotherapy in Patients With Esophageal Cancer and Lung Cancer","Inclusion Criteria:\n\n* Age ≥18 years old, gender not limited;\n* Histologically or cytologically confirmed untreated locally advanced\u002Fmetastatic esophageal cancer and lung cancer;\n* Has not received any chemotherapy drugs in the past (anti-tumor drugs are not used for cancer treatment);\n* Plan to receive at least 4 cycles of chemotherapy combined with immunotherapy based on cisplatin and carboplatin;\n* Expected survival period ≥3 months;\n* Eastern Cooperative Oncology Group (ECOG) Physical Condition score: 0 or 1 point;\n* Good organ function, meeting the following criteria:\n\n  1. Neutrophil count ≥1.5×109\u002FL;\n  2. Hemoglobin ≥ 90g\u002FL;\n  3. Platelet count ≥ 100×109\u002FL;\n  4. Total bilirubin ≤1.5×ULN In patients without known liver metastases, aspartate aminotransferase ≤2.5×ULN and\u002For alanine aminotransferase ≤2.5×ULN (for patients with liver metastases, it can be relaxed to ≤5×ULN);\n\n  f: Serum creatinine ≤1.5×ULN or creatinine clearance rate ≥ 50ml\u002Fmin; g: Electrocardiogram: QTc≤450ms (for males), QTc≤470ms (for females); h: Cardiac color Doppler ultrasound: LVEF (left ventricular ejection fraction) ≥50%;\n* Fertile female subjects and male subjects whose partners are fertile women need to adopt an effective contraceptive measure from the time of signing the informed consent form until 6 months after the last administration. Female subjects with fertility must have a negative blood pregnancy test within 72 hours before randomization. And it must be non-lactation period;\n* Clearly understand and voluntarily participate in this research, and sign the informed consent form by oneself.\n\nExclusion Criteria:\n\n* Abdominal (including the diaphragmatic plane and below) or pelvic radiotherapy was received within 7 days prior to randomization, or is planned to be received within 1 to 8 days of treatment;\n* It is planned to administer chemotherapy drugs with a high risk of vomiting within 2 to 8 days after platinum infusion.\n* Plan to receive chemotherapy regimens including common paclitaxel (using castor oil as the solvent);\n* Take drugs with potential antiemetic effects within 2 days before randomization: The first-generation 5-HT3 receptor antagonists (such as ondansetron), phenthiazide drugs (such as prochlorazine), butanylbenzene drugs (such as haloperidol), benzamides (such as metoclopramide), domperidone, cannabinoids, traditional Chinese medicines with potential antiemetic effects, scopolamine, cyclezine, etc.\n* Start treatment with benzodiazepines or opioid preparations within 2 days before randomization (except for triazolam, temazepam or midazolam taken alone daily);\n* Subjects who began using morphine within 7 days before randomization (except those taking a stable dose);\n* Within 7 days before randomization, systemic corticosteroid therapy (including but not limited to dexamethasone, hydrocortisone, methylprednisolone or prednisolone) or sedative antihistamines (such as diphenhydramine) were received (Note: Single use of steroids is allowed to prevent contrast agent allergy and local administration or inhalation), except for those who need hormone pretreatment one day before chemotherapy.\n* Palonosetron was used within 14 days prior to randomization;\n* Use NK-1 receptor antagonists within 28 days before randomization;\n* Specific CYP3A4 substrates (terfenadine, cisapride, asemidazole) or CYP3A4 inhibitors (such as ritonavir, clarithromycin, ketoconazole or itraconazole, diltiazem, etc.) were used within 7 days before randomization. Strong CYP3A4 inducers (such as phenobarbital, rifampicin, phenytoin and carbamazepine) or specific CYP2D6 substrates (thiolidazine, pimozide) were used within 28 days before randomization;\n* Vomiting and\u002For retching and nausea occurred within 24 hours before randomization; Subjects with symptomatic brain metastases;\n* Accompanied by poorly controlled serous cavity effusion, including pleural effusion, ascites, and pericardial effusion (those that have been controlled after treatment and remained stable for ≥2 weeks can be included);\n* Having severe cardiovascular diseases within 3 months prior to randomization, including but not limited to acute myocardial infarction, unstable angina pectoris, significant valvular or pericardial disease, history of ventricular tachycardia, symptomatic chronic heart failure (New York Heart Association \\[NYHA\\] grades II to IV), and history of severe cardiac conduction abnormalities (such as torus cuspidata ventricular tachycardia);\n* Poorly controlled hypertension (two consecutive resting systolic blood pressures ≥160mmHg and\u002For diastolic blood pressures ≥100mmHg) before randomization;\n* Those with combined active hepatitis B (HBV DNA≥2000 IU\u002FmL or 104 copies\u002FmL), active hepatitis C (HCV-Ab positive and HCV-RNA≥ upper limit of normal value), acquired immune deficiency syndrome (AIDS) or positive HIV test, and positive syphilis test;\n* Concomitant diseases that prevent dexamethasone from being taken, such as active infections (like pneumonia) or any uncontrolled diseases (such as diabetic ketoacidosis, gastrointestinal obstruction, etc.);\n* Known contraindications of NK-1 receptor antagonists, 5-HT3 receptor antagonists or dexamethasone;\n* Having participated in other clinical trials within 30 days prior to randomization (based on the use of the study drug);\n* Subjects who the researchers consider to have other circumstances that make them unsuitable to participate in this study.",{"count":73,"type":21},120,[75],"PHASE2","This study was a randomized, parallel, cohort study to evaluate the efficacy and safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in preventing nausea and vomiting caused by multi-cycle immunotherapy and chemotherapy in patients with esophageal cancer and lung cancer. A total of 120 subjects are planned to be enrolled, with 60 in each cohort. 40% of the subjects will undergo an interim analysis upon completion of the study.\n\nThe trial consists of a screening period, a treatment period and a safety follow-up period. Drug treatment was administered in accordance with the trial protocol, and then the corresponding follow-up and examination were completed in accordance with the trial process table. During the research period, if the researcher assesses that the subjects indeed need to use remedial antiemetic drugs, remedial treatment can be carried out based on clinical practice. The specific types, usage, dosage and frequency of the drugs are determined by the researcher.",[28,78],"Lung Cancer","2026-05-24",{"date":81,"type":36},"2026-06-01",{"date":83,"type":36},"2025-11-01",{"date":85,"type":21},"2027-01-31",{"name":87,"class":43},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":89,"slug":90,"hasResults":12,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":4},"100638325","statewide-unified-network-for-remote-intervention-of-strength-and-exercise-100638325","NCT07596732","Statewide Unified Network for Remote Intervention of Strength and Exercise","SUNRISE","Inclusion Criteria:\n\n* Gastrointestinal cancer (esophageal, gastric, pancreatic, colon, and rectal) treated with chemotherapy (and other treatments, as clinically indicated) before surgery OR Lung cancer (non-small cell and small-cell) treated with chemotherapy (and other treatments, as clinically indicated) for advanced- or extensive-stage disease.\n* Completion of the modified version of the Physical Activity Readiness Questionnaire.\n\nExclusion Criteria:\n\n* Actively treated for another non-gastrointestinal or non-lung malignancy (surveillance with observation is allowed).\n* Engage in more than 150 minutes per week of aerobic physical activity and two or more sessions of muscle strengthening activity per week over the last three months (self-report).\n* Unable to walk for 6 minutes or two city blocks independently (self-report).\n* Enrollment in another study that intervenes upon physical activity, diet, or body composition as a primary objective (self-report).\n* Unable to read and speak English.\n* No access to a reliable internet connection.\n* Currently an AdventHealth employee.",{"count":73,"type":21},[24],"This study will evaluate whether a remotely delivered exercise program can improve chemotherapy tolerability in patients with gastrointestinal or lung cancer receiving chemotherapy.\n\nIn this decentralized, digital randomized clinical trial, up to 120 adults with gastrointestinal or lung cancer will be randomized to either a home-based aerobic and resistance exercise program or home-based progressive stretching program. All study activities will be conducted remotely using digital technologies and home-based assessments. Participants in both groups will receive Bluetooth-enabled wearable devices for monitoring physical activity, body weight, blood pressure, and other health measures.\n\nThe primary objective is to determine whether exercise improves chemotherapy relative dose intensity compared with stretching. The intervention will continue throughout chemotherapy treatment or for up to 32 weeks.",[99,28,100,101,102,78],"Gastric Cancer (Diagnosis)","Pancreas Cancer","Colon Cancer","Rectal Cancer","NOT_YET_RECRUITING","2026-05-13",{"date":106,"type":36},"2026-05-19",{"date":108,"type":21},"2026-07-01",{"date":110,"type":21},"2027-12-31",{"name":112,"class":43},"AdventHealth Translational Research Institute",{"id":114,"slug":115,"hasResults":12,"nctId":116,"briefTitle":117,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":121,"phases":4,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":44},"100597854","multimodal-deep-learning-for-predicting-treatment-response-to-neoadjuvant-chemoimmunotherapy-in-esophageal-cancer-100597854","NCT07063901","Multimodal Deep Learning for Predicting Treatment Response to Neoadjuvant Chemoimmunotherapy in Esophageal Cancer","Inclusion Criteria:\n\n1. Patients with histologically confirmed esophageal cancer based on biopsy results;\n2. Patients recommended for neoadjuvant chemoimmunotherapy following multidisciplinary team (MDT) discussion or evaluation by thoracic surgery specialists;\n3. Patients who received neoadjuvant chemoimmunotherapy;\n4. Patients with complete imaging data before and after neoadjuvant treatment.\n\nExclusion Criteria:\n\n1. Patients deemed eligible for surgery by the thoracic surgery team but who refused surgical treatment;\n2. Patients with missing or poor-quality CT images;\n3. Patients with concurrent malignancies other than esophageal cancer;\n4. Patients with incomplete clinical data.",{"count":120,"type":21},200,"OBSERVATIONAL","This observational study aims to investigate a clinical cohort of patients with locally advanced esophageal cancer undergoing neoadjuvant chemoimmunotherapy. By integrating multimodal clinical data-including demographic characteristics, medical history, imaging studies, pathological findings, and laboratory tests-and employing deep learning algorithms, the study seeks to develop predictive models for the early and accurate assessment of treatment response prior to surgery. Specifically, this study focuses on addressing the following key scientific questions:\n\n1. Can multimodal clinical data be used to construct an accurate model for predicting pathological complete response (pCR) following neoadjuvant therapy?\n2. Can deep learning models enable early identification of patients with suboptimal response to neoadjuvant therapy, defined as stable disease (SD) or progressive disease (PD), before surgery?",[28],"2026-05-11",{"date":126,"type":36},"2026-05-12",{"date":128,"type":36},"2025-06-01",{"date":130,"type":21},"2026-05-31",{"name":132,"class":43},"Central South University",{"id":134,"slug":135,"hasResults":12,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":144,"conditions":145,"keywords":149,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":44},"100637668","phase-1-a-phase-1-first-in-human-study-of-crpa1a2-a-mage-a1hla-a0201-bispecific-t-cell-engager-in-patients-with-solid-tumors-100637668","NCT07583316","A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1\u002FHLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors","A Phase I First-In-Human Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of CRPA1A2, a Bispecific T Cell Engager, in Patients With HLA-A*02:01 and MAGE-A1 Positive Advanced Solid Tumors","Inclusion Criteria:\n\n1. Patients with a histological and\u002For cytological confirmed locally advanced or metastatic unresectable solid tumor (including but not limited to esophageal squamous cell carcinoma, hepatocellular carcinoma, head and neck squamous cell carcinoma and lung squamous cell carcinoma) who have experienced disease progression following available standard therapy and for whom no further standard treatment options are available.\n2. Patients with confirmed positive expression of MAGE-A1 (H-score ≥1, testing by IHC for FFPE) by central lab.\n3. Patients with positive HLA-A\\*02:01 (confirmed by the central lab).\n4. There must be at least one measurable lesion per RECIST v1.1 criteria. (Lesions that have received radiotherapy previously cannot be considered target lesions unless there is evident progression after radiotherapy).\n5. Eastern Cooperative Oncology Group (ECOG) performance status: 0-1.\n6. Life expectancy ≥ 3 months, in the opinion of the investigator.\n7. Has adequate organ function, as demonstrated by laboratory values obtained during the screening period.\n8. Participants (both males and females) of childbearing potential must agree to use highly efficient contraception from the time of signing the informed consent form until 6 months after the last dose of the investigational drug.\n\nExclusion Criteria:\n\n1. Patients with history of other malignancies (within 2 years prior to signing the ICF) are excluded, except for those with cured stage IB or earlier stage cervical cancer, non-invasive basal cell or squamous cell skin cancer, malignant melanoma in complete remission (CR) for over 10 years, or other malignancies in complete remission (CR) for over 5 years.\n2. Patients with positive HLA-A\\*02:05 (confirmed by the central lab).\n3. Patients with known sensitivity or immediate hypersensitivity to any components of CRPA1A2 or ingredients of CRPA1A2 injection.\n4. Patients who have been exposed to other MAGE-A1 targeted therapy.\n5. With clinically significant cardiovascular diseases, including but not limited to:\n\n   1. History of heart failure, myocardial ischemia or infarction, unstable angina, arrhythmias, or New York Heart Association (NYHA) Class III-IV within the past 6 months or currently.\n   2. With prolonged QT\u002FQTc intervals on the electrocardiogram during the screening period (QTcF: \\> 480 ms).\n   3. Echocardiogram (ECHO) indicates a left ventricular ejection fraction (LVEF) of ≤50% at screening.\n   4. Poorly controlled hypertension at screening (systolic blood pressure ≥150 mmHg, diastolic blood pressure ≥100 mmHg) despite pharmacological treatment.\n   5. History of vascular angioplasty, coronary artery bypass grafting, or other cardiac surgical procedures.\n6. With clinically significant active hepatitis B, HBsAg or HBcAb positive and have an HBV-DNA level above the detection limit at screening (i.e., the upper limit of normal values at each research center's laboratory). With the exception for those that have achieved HBV-DNA negativity after antiviral treatment and have received at least 2 weeks of antiviral therapy before the initial dosing. Additionally, they must be willing to continue antiviral therapy for hepatitis B throughout the study period. For patients with hepatocellular carcinoma, HBV DNA must be \\\u003C1000 IU\u002FmL for study eligibility.\n7. Clinically significant active hepatitis C, indicated by positive HCV antibodies and HCV-RNA levels higher than the detection limit at screening (upper limit of normal values).\n8. Positive Treponema pallidum antibodies (TP-Ab) and positive result for nonspecific syphilis antibodies titer (RPR) at screening.\n9. Prior or concurrent therapies\u002Fprocedures that may confound study evaluation or increase risk, including recent participation in another clinical study; recent anticancer therapy, investigational treatment, or invasive investigational medical device use; major surgery without full recovery; prior solid organ transplantation or allogeneic hematopoietic stem cell transplantation; recent autologous hematopoietic stem cell transplantation; or planned transplantation during the study period.\n10. Active, uncontrolled, or clinically significant medical conditions that may increase the risk of study participation or interfere with study assessments, including severe infection; symptomatic or uncontrolled central nervous system or leptomeningeal metastases; clinically significant pulmonary disease (e.g., interstitial lung disease\u002Fpneumonitis); coagulation or bleeding disorders; autoimmune disease or immunodeficiency (including HIV infection); or significant neurologic or psychiatric disorders.\n11. Unresolved toxicities or other conditions considered by the investigator to make the participant unsuitable for the study, including failure to recover adequately from prior anticancer treatment-related toxicities, prior Grade ≥2 ICANS after T-cell engager or CAR-T therapy, clinically significant abnormal laboratory findings, or other severe\u002Funcontrolled acute or chronic diseases, alcohol abuse, or substance misuse.",{"count":141,"type":21},192,[143],"PHASE1","This is a Phase I, first-in-human, open-label study of CRPA1A2, a bispecific T-cell engager, in participants with HLA-A\\*02:01-positive and MAGE-A1-positive advanced solid tumors. The study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of CRPA1A2, and to identify recommended dose(s) for further evaluation.\n\nThe study consists of 2 parts: a dose escalation part (Part A) and a dose optimization part (Part B). In Part A, participants will receive escalating doses of CRPA1A2 to determine the recommended dose(s) for optimization, with additional backfill cohorts permitted. In Part B, 2 to 3 selected recommended dose(s) will be further evaluated in participants with selected tumor types to better characterize safety and preliminary anti-tumor activity.\n\nCRPA1A2 will be administered by intravenous infusion in 28-day cycles, starting at 0.0003 mg\u002Fkg. Weekly dosing is planned, although alternative dosing schedules may be explored based on emerging data. Treatment will continue until disease progression, intolerable toxicity, initiation of new anti-tumor therapy, other discontinuation criteria are met, or study termination.",[146,28,147,148],"Lung Cancer (Locally Advanced or Metastatic)","Head and Neck Cancer","Hepatocellular Carcinoma (HCC)",[150,151,152,153,154],"CRPA1A2","Bispecific T-cell engager","Advanced solid tumors","HLA-A*02:01","MAGE-A1","2026-05-06",{"date":104,"type":36},{"date":158,"type":21},"2026-05-29",{"date":160,"type":21},"2030-09-30",{"name":162,"class":163},"Corregene Biotechnology Co., Ltd","INDUSTRY",{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":22,"phases":173,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":44},"100453641","phase-1-ca-4948-in-combination-with-folfoxpd-1-inhibitor---trastuzumab-for-untreated-unresectable-gastric-and-esophageal-cancer-100453641","NCT05187182","CA-4948 in Combination With FOLFOX\u002FPD-1 Inhibitor +\u002F- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer","Phase I Trial of CA-4948 in Combination With FOLFOX\u002FPD-1 Inhibitor +\u002F- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer","Inclusion Criteria:\n\n* Advanced unresectable or metastatic histologically or cytologically confirmed adenocarcinoma or squamous cell carcinoma of the stomach, gastroesophageal junction, or esophagus\n* Measurable or evaluable disease defined by RECIST 1.1.\n* Lesions amenable to research biopsy. This criteria can be waived by the PI after documented discussion with the treating physician.\n* Known HER2 status if histology is adenocarcinoma prior to enrollment; results from local CLIA laboratory is acceptable.\n\n  * For Dose Escalation, patients are required to have documented HER2 negative cancer.\n  * For Dose Expansion, patients will be enrolled to either HER2 positive or negative cohorts at the time of enrollment\n* No prior systemic treatment for unresectable\u002Fadvanced gastric, GEJ, or esophageal cancer.\n\n  * Neoadjuvant or adjuvant systemic therapy is allowed; however, surgical resection and adjuvant chemotherapy should have been \\> 3 months from planned C1D1.\n  * Up to two prior cycles of FOLFOX is allowed.\n  * Definitive chemoradiation is allowed if the last date of chemotherapy or radiation (whichever is more recent) is \\> 3 months from planned C1D1.\n  * Prior palliative radiation therapy, including brain radiation, in the unresectable setting is allowed, but the last treatment date should be \\>10 days from planned C1D1.\n* At least 18 years of age\n* ECOG performance status 0 or 1\n* Adequate bone marrow and organ function as defined below:\n\n  * Absolute neutrophil count ≥ 1.5 K\u002Fcumm\n  * Platelets ≥ 100 K\u002Fcumm\n  * Hemoglobin ≥ 9.0 g\u002FdL\n  * Total bilirubin ≤ 1.5 x IULN or ≤ 3 x IULN in patients with documented Gilbert's syndrome\n  * AST(SGOT)\u002FALT(SGPT) ≤ 2.0 x IULN, unless there are liver metastases in which case AST and ALT ≤ 5.0 x IULN\n  * PT\u002FINR ≤ 1.5 x IULN\n  * aPTT ≤ 1.5 x IULN\n  * Creatinine clearance ≥ 35 mL\u002Fmin by Cockcroft-Gault\n* Creatinine phosphokinase (CPK) elevation at screening \\\u003C Grade 2 (CPK \\\u003C 2.5 x IULN)\n* Patients on a cholesterol lowering statin must be on a stable dose with no dose changes within 3 weeks prior to study start.\n* Expansion Cohort B patients only: LVEF above LLN as assessed by MUGA or ECHO\n* The effects of CA-4948 on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of the study, and 3 months after completion of the study\n* Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).\n\nExclusion Criteria:\n\n* Current use or anticipated need for alternative, holistic, naturopathic, or botanical formulations used for the purpose of cancer treatment. Use of medical marijuana is permitted.\n* A history of other malignancy with the exception of 1) malignancies for which all treatment was completed at least 2 years before registration and the patient has no evidence of disease; 2) or known indolent malignancies that do not require treatment and will likely not alter the course of treatment of metastatic gastric, GEJ, or esophageal cancer.\n* History of allogeneic organ or stem cell transplant\n* Currently receiving any other investigational therapeutic agents. Investigational tracers related to imaging studies are allowed with a 7 day-washout.\n* Currently have an intraluminal GI stent (gastric, esophageal, small bowel, colon). Biliary stents are allowed.\n* History of clinically relevant bleeding from their tumor(s). Includes but is not limited to bleeding tumor requiring RBC transfusion, or bleeding requiring more than one endoscopic intervention.\n* Untreated ulcerating tumor. Patients who are endoscopically treated must be assessed by the study PI or delegate for eligibility.\n* Use of systemic therapeutic anticoagulation, including daily baby aspirin, within 5 half-lives of the anticoagulant prior to C1D1. Patients can receive heparin or alteplase flush in their ports.\n* Use of anti-platelet therapies (i.e. P2Y12 inhibitors (clopidogrel, prasugrel, etc.), within 5 half-lives of the anti-platelet therapy prior to C1D1.\n* Use of NSAIDs within 5 half-lives of the NSAID prior to C1D1.\n* Clinically active CNS metastasis; treated and asymptomatic metastasis allowed at the discretion of the PI. Radiotherapy to the brain must be completed \\> 10 days prior to planned C1D1.\n* A history of allergic reactions attributed to compounds of similar chemical or biologic composition to CA-4948, FOLFOX, nivolumab, trastuzumab or other agents used in the study.\n* Concomitant use of drugs with a known risk of causing prolonged QTc and\u002For Torsades de Pointes or a history of risk factors for Torsades de Pointes.\n* Presence of interstitial lung disease or pneumonitis ≥ G2\n* Administration of a live attenuated vaccine within 30 days prior to enrollment.\n* QTc (Bazett) \\>470ms on screening EKG\n* Gastrointestinal condition which could impair absorption of CA-4948 or inability to ingest CA-4948\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia\n* Pregnant and\u002For breastfeeding. Women of childbearing potential must have a negative pregnancy test within 7 days of study entry.\n* Patients with HIV are eligible unless their CD4+ T-cell counts are \\\u003C 350 cells\u002FmcL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to registration. Concurrent treatment with effective ART according to DHHS treatment guidelines is recommended. Recommend exclusion of specific ART agents based on predicted drug-drug interactions (i.e., for sensitive CYP3A4 substrates, concurrent strong CYP3A4 inhibitors (ritonavir and cobicistat) or inducers (efavirenz) should be contraindicated).\n* Participants with active, known or suspected autoimmune disease. Participants with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, euthyroid participants with a history of Grave's disease (participants with suspected autoimmune thyroid disorders must be negative for thyroglobulin and thyroid peroxidase antibodies and thyroid stimulating immunoglobulin prior to first dose of study treatment), psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll after discussing with the PI.\n* Participants with a condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of study treatment except for adrenal replacement steroid doses \\> 10 mg daily prednisone equivalent in the absence of active autoimmune disease. Note: treatment with a short course of steroids (\\\u003C 5 days) up to 7 days prior to initiating study treatment is permitted. Inhaled intranasal, intra-articular, and topical steroid uses are permitted.\n* Patients are unwilling to adhere to the lifestyle guidance in protocol.",{"count":172,"type":21},42,[143],"This is a phase I trial of CA-4948 in combination with FOLFOX\u002FPD-1 inhibitor with or without trastuzumab for unresectable gastric, GEJ, and esophageal cancer. During the Dose Escalation portion of the study, different dose levels of CA-4948 in combination with FOLFOX\u002Fnivolumab will be evaluated by BOIN algorithm.\n\nDose Expansion will include Cohorts A and B. Expansion Cohort A will enroll up to 12 patients with HER2 negative gastric, GEJ, and esophageal cancer at the expansion dose of CA-4948 determined during Dose Escalation and will use the same treatment regimen of FOLFOX\u002Fnivolumab. Expansion Cohort B will investigate CA-4948 at the dose determined during Dose Escalation in combination with FOLFOX\u002Fpembrolizumab and trastuzumab in up to 12 patients with HER2 positive disease; however, the initial 6 patients will be considered safety lead-in to confirm the safety and tolerability of this combination; if determined to be safe, an additional 6 patients will be enrolled for a total of 12 in Cohort B.",[176,177,178,28,179],"Gastric Cancer","Esophageal Cancer","Stomach Cancer","Gastroesophageal Junction Cancer","2026-04-21",{"date":182,"type":36},"2026-04-27",{"date":184,"type":36},"2023-06-02",{"date":186,"type":21},"2029-04-30",{"name":188,"class":43},"Washington University School of Medicine",{"id":190,"slug":191,"hasResults":12,"nctId":192,"briefTitle":193,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":121,"phases":4,"briefSummary":198,"conditions":199,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":44},"100249843","mayo-clinic-upper-digestive-disease-survey-100249843","NCT02530983","Mayo Clinic Upper Digestive Disease Survey","UDD","Inclusion Criteria:\n\n* Patients undergoing or having already undergone an esophagectomy or esophageal reconstruction.",{"count":197,"type":21},1000,"The Mayo Clinic Conduit Report Card Questionnaires have been created in order to have a consistent evaluation tools for patients undergoing esophageal reconstruction or treatment or patients that are experiencing an upper digestive disease in order to standardize and validate outcome measures. Data will be used to establish the validation of the questionnaires\u002Fsurvey. Data will also lead to the establishment of \"normal\" or expected scores for patients undergoing each type of esophagectomy procedure and for upper digestive diseases. Data will contribute to creating treatment algorithms for symptom management for upper digestive diseases and for post-operative complications and symptoms as well as contribute to pre-operative education.",[200,201,202,177,28,203,204,205,206],"Esophageal Neoplasms","Cancer of Esophagus","Cancer of the Esophagus","Neoplasm, Esophageal","Esophagectomy","Abnormalities, Digestive System","Digestive System Abnormalities","2026-03-24",{"date":209,"type":36},"2026-03-30",{"date":211,"type":36},"2015-08-15",{"date":213,"type":21},"2028-12",{"name":215,"class":43},"Mayo Clinic",{"id":217,"slug":218,"hasResults":12,"nctId":219,"briefTitle":220,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":121,"phases":4,"briefSummary":224,"conditions":225,"keywords":226,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":44},"100493546","retrospective-review-of-esophageal-cancer-at-mskcc-100493546","NCT05706558","Retrospective Review of Esophageal Cancer at MSKCC","Inclusion Criteria:\n\n* Histologically confirmed esophageal adenocarcinoma (EAC) or esophageal squamous cell carcinoma (ESCC) undergoing esophagectomy\n* Pathologic staged T3 tumors (pT3)\n\nExclusion Criteria:\n\n* Pathologic staged T0-2 (pT0-2) or T4 tumors (pT4)\n* Patients with histologic types other than EAC or ESCC, dysplasia or carcinoma in situ without tumor invasion,\n* Patients undergoing salvage esophagectomy\n* Evidence of distant metastatic disease\n* Patients with a positive proximal or distal margin",{"count":223,"type":21},4000,"Residual tumor at the proximal or distal margin after esophagectomy is a known prognostic factor for poor survival outcomes in patients with esophageal cancer; however, the significance of the circumferential resection margin (CRM) remains controversial. In this study, the investigators sought to evaluate the prognostic significance of the CRM in patients with esophageal cancer undergoing resection.",[177,28],[177,28,227,228],"Memorial Sloan Kettering Cancer Center","16-1631","2026-03-06",{"date":231,"type":36},"2026-03-09",{"date":233,"type":36},"2016-12-13",{"date":235,"type":21},"2027-02",{"name":227,"class":43},{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":22,"phases":246,"briefSummary":247,"conditions":248,"keywords":250,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":263},"100598359","phase-2-ivonescimab-in-comb-with-folfox-in-advanced-her2-neg-gea-100598359","NCT07070466","Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA","A Single-Arm, Phase II Study of Ivonescimab in Combination With FOLFOX in Advanced HER2 Negative Gastroesophageal Adenocarcinomas","Inclusion Criteria:\n\n* Patients must have a pathologically confirmed diagnosis of adenocarcinoma of the esophagus, gastroesophageal junction, stomach. Squamous cell tumors are excluded. Patients with locally tested HER2 positive tumors (HER2+) tumors are excluded.\n* Participants must have disease that can be evaluated radiographically. This includes disease that may be measurable or non-measurable as per RECIST version 1.1.\n* Patients may not have received prior therapy for Stage IV disease. Patients may have received prior adjuvant therapy if more than 6 months have elapsed between the end of adjuvant therapy and registration.\n* Age ≥18 years old. Because there is no dosing or adverse event data for ivonescimab with FOLFOX in participants \\\u003C18 years of age, children are excluded from this study.\n* ECOG Performance status of 0-2\n* Participants must meet the following organ and marrow function as defined below:\n\n  1. absolute neutrophil count ≥1,500\u002FmcL\n  2. hemoglobin \\> 9.0 g\u002FdL\n  3. platelets ≥100,000\u002FmcL\n  4. total bilirubin ≤ 1.5x institutional upper limit of normal (ULN). For patients with liver metastases or confirmed\u002Fsuspected Gilbert syndrome, TBIL ≤3 × ULN\n  5. AST(SGOT)\u002FALT(SGPT) ≤2.5 × institutional ULN. For patients with liver metastases, AST and ALT ≤ 5 × ULN\n  6. Creatinine ≤ institutional ULN OR glomerular filtration rate (GFR) ≥50 mL\u002Fmin.\n  7. Urine protein \\\u003C 2+ or 24-hour protein quantification \\\u003C 1.0 grams.\n  8. Coagulation: prothrombin time (PT) or international normalized ratio (INR) ≤ 1.5 × ULN, and partial prothrombin time (PTT) or activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN (unless abnormalities are unrelated to coagulopathy) This applies only to patients who are not on therapeutic anti-coagulation. Patients receiving therapeutic anti-coagulation should be on a stable dose.\n* For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n* Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n* Participants with brain metastases (active brain metastases) or leptomeningeal disease are not eligible. Patients with treated brain metastases who are off systemic steroids \\> 2 weeks and have documented radiographic stability over 4 weeks since initial brain metastasis diagnosis may be considered in discussion with the overall principal investigator.\n* Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n* The effects of ivonescimab on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Contraception should continue for 9 months from the last dose of any study medication.\n* Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 9 months after completion of ivonescimab administration.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Prior treatment with a PD-1 or PD-L1 inhibitor is exclusionary unless this therapy was completed \\> 6 months prior to the time of enrollment as part of adjuvant therapy.\n* Major surgical procedures or serious trauma within 4 weeks prior to enrolment, or plans for major surgical procedures within 4 weeks after the first dose (as determined by the investigator). Minor local procedures (excluding central venous catheterization and port implantation) within 3 days prior to randomization.\n* Participants who have not recovered from adverse events due to prior adjuvant anti-cancer therapy except for alopecia or peripheral neuropathy grade 1 or less.\n* Participants who are receiving any other investigational agents for this condition are not eligible.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to ivonescimab. Patients with prior oxaliplatin and\u002For 5FU allergic reactions during adjuvant therapy are allowed if they have undergone prior desensitization with allergy and documented tolerance at standard dosing after desensitization.\n* Pregnant women are excluded from this study because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding should be discontinued if the mother is treated with ivonescimab. These potential risks may also apply to other agents used in this study.\n* History of perforation of the gastrointestinal tract and\u002For fistula, history of gastrointestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), extensive bowel resection (partial colectomy or extensive small bowel resection) within 6 months prior to randomization.\n* Clinically significant hypertension with systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg after oral antihypertensive therapy.\n* History of any grade arterial thromboembolic event, venous thromboembolic event of Grade 3 and above as specified in National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) 5.0, transient ischemic attack, cerebrovascular accident, hypertensive crisis, or hypertensive encephalopathy within 12 months prior to randomization.\n* Participants with a documented history of impaired wound healing are excluded.\n* Participants with a history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n* Participants with uncontrolled intercurrent illness that would interfere with ability to participate in the opinion of the treating investigator.\n* Participants with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Unstable angina, myocardial infarction, congestive heart failure (New York Heart Association \\[NYHA\\] classification ≥ grade 2) or unstable vascular disease (eg, aortic aneurysm at risk of rupture, Moyamoya disease) that required hospitalization within 12 months prior to randomization, or other cardiac impairment that may affect the safety evaluation of the study drug (eg, poorly controlled arrhythmias, myocardial ischemia).\n* Subjects with any condition requiring systemic treatment with either corticosteroids (\\>2mg daily dexamethasone equivalent) or other immunosuppressive medications within 14 days of treatment. Premedication for hypersensitivity reactions (e.g. to contrast for CT or gadolinium for MRI) is allowed.\n* Active systemic infection requiring intravenous antibiotics or intravenous monoclonal antibody treatments within 7 days of cycle 1 day 1.\n* Participants with a known history of Human Immunodeficiency Virus (HIV) infection are excluded unless they meet all of the following criteria:\n\n  * Stable antiretroviral therapy (ART) for at least 12 weeks prior to enrollment\n  * No history of AIDS-defining conditions.\n  * CD4+ T-cell count ≥ 350 cells\u002Fmm³ at screening\n  * HIV viral load ≤ 50 copies\u002FmL at screening.\n  * No significant comorbidities associated with HIV infection that could interfere with the safety or efficacy of the investigational treatment.\n  * No concurrent use of prohibited medications that may interfere with the study drug or cancer therapy\n* History of bleeding tendencies or coagulopathy and\u002For clinically significant bleeding symptoms or risk within 4 weeks prior to randomization, including but not limited to:\n\n  * Hemoptysis (defined as coughing up ≥ 0.5 teaspoon of fresh blood or small blood clots). Note: transient hemoptysis associated with diagnostic bronchoscopy is allowed.\n  * Nasal bleeding \u002Fepistaxis (bloody nasal discharge is allowed)\n  * Current use of prophylactic or full-dose anticoagulants or anti-platelet agents for therapeutic purposes that is not stable prior to randomization is not allowed. The use of full-dose anticoagulants is permitted as long as the international normalized ratio (INR) or activated partial thromboplastin time (aPTT) is within therapeutic limits according to the medical standard of the enrolling institution.\n* History of non-infectious pneumonitis requiring therapy within 4 weeks of registration.",{"count":245,"type":21},40,[75],"This is a single arm, open-label, phase II trial investigating the combination of ivonescimab with standard FOLFOX chemotherapy in 1L therapy for HER2- GEA.",[249,28,178],"Stomach Cancer Stage IV",[251,252,253,254],"stomach cancer","esophageal cancer","Phase 2","Immunotherapy","2026-03-04",{"date":229,"type":36},{"date":258,"type":36},"2025-10-10",{"date":260,"type":21},"2028-09-01",{"name":262,"class":43},"Massachusetts General Hospital",2,{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":272,"targetDuration":274,"studyType":121,"phases":4,"briefSummary":275,"conditions":276,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":319},"100368284","the-momentum-study-the-multiple-outcome-evaluation-of-radiation-therapy-using-the-mr-linac-study-100368284","NCT04075305","The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","MOMENTUM","Inclusion Criteria:\n\n* Patient is to undergo or has completed imaging or treatment procedures on an MR-Linac;\n* Patient provides written, informed consent;\n* Patient is 18 years old or older.\n\nExclusion Criteria:\n\n* MRI exclusion criteria, including\n* MRI contraindications as per usual clinical care, such as (possible) pregnancy; claustrophobia and metal or electronic implants not compatible with MRI.",{"count":273,"type":21},8000,"2 Years","The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.",[277,278,279,280,281,282,283,284,285,286,287,288,102,289,290,78,291,292,177,28,293,294,295,296,297,298,299,147,300,301,302,303,304,305,306,307,308,309],"Oncology","Breast Cancer","Prostate Cancer","Gynecologic Cancer","Brain Tumor","Brain Cancer","Gynecologic Tumor","Prostate Tumor","Prostate Neoplasm","Breast Tumor","Radiation Toxicity","Quality of Life","Rectal Tumor","Rectal Neoplasms","Lung Tumor","Lung Neoplasm","Esophageal Tumor","Esophageal Neoplasm","Esophagus Tumor","Esophagus Neoplasm","Pancreatic Cancer","Pancreatic Tumor","Pancreatic Neoplasms","Head and Neck Neoplasms","Head and Neck Tumor","Tumor","Neoplasms","Bladder Cancer","Bladder Neoplasm","Liver Cancer","Liver Neoplasms","Liver Metastases","Oligometastases","2026-03-03",{"date":312,"type":36},"2026-03-05",{"date":314,"type":36},"2019-02-01",{"date":316,"type":21},"2030-08-01",{"name":318,"class":43},"UMC Utrecht",18,{"id":321,"slug":322,"hasResults":12,"nctId":323,"briefTitle":324,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":326,"targetDuration":4,"studyType":121,"phases":4,"briefSummary":328,"conditions":329,"keywords":330,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":341,"locationsCount":44},"100626790","clinical-study-on-noninvasive-evaluation-of-ivonescimab-antibody-distribution-and-expression-in-esophageal-cancer-patients-by-89zr-ak112-pet-imaging-100626790","NCT07440212","Clinical Study on Noninvasive Evaluation of Ivonescimab Antibody Distribution and Expression in Esophageal Cancer Patients by 89Zr-AK112 PET Imaging","Inclusion Criteria:\n\n* 1\\) Patients aged over 18 years with no gender restriction;\n* 2\\) Patients diagnosed with esophageal cancer;\n* 3\\) Patients eligible for 89Zr-AK112 PET examination;\n* 4\\) Written informed consent signed by the subject or their legal guardian.\n\nExclusion Criteria:\n\n* 1\\) Patients who have received antitumor therapy prior to PET\u002FCT scanning;\n* 2\\) Patients with severe diseases that cannot tolerate PET\u002FCT scanning;\n* 3\\) Alternative subjects with contraindications to PET\u002FCT scanning;\n* 4\\) Radiation exposure exceeding 50 mSv dose in the past year;\n* 5\\) Alternative subjects who underwent major surgery within the past 3 months; those who received experimental drugs or devices (with unclear efficacy or safety) within the past 1 month;\n* 6\\) Alternative subjects with any clinical conditions that the principal investigator of this study considers may cause or pose potential hazards from the investigational product.",{"count":327,"type":21},50,"As a humanized bispecific antibody targeting PD-1 and VEGF-A, everolizumab exhibits high specificity for binding PD-1 and VEGF-A in vivo. This critical property was systematically validated in a recent molecular imaging study based on positron emission tomography (PET). The study utilized radiolabeled everolizumab to construct an everolizumab PET probe, enabling non-invasive and dynamic monitoring of drug distribution and targeting behavior in living organisms. The results demonstrated that the PET probe exhibited excellent target tissue enrichment in the HCT-116 colorectal cancer xenograft model. In vivo PET imaging revealed a sustained increase in tumor uptake over time, peaking at 48 hours post-administration at 13.73 ± 0.95% ID\u002Fg, indicating strong tumor retention. Blocking experiments (pre-injection of excess everolizumab) significantly reduced tumor uptake to 5.20 ± 0.10% ID\u002Fg (P=0.00011), strongly supporting that its in vivo targeting is mediated by PD-1\u002FVEGF-A-specific interactions rather than nonspecific accumulation. At 48 hours, the tumor-to-muscle signal-to-noise ratio (T\u002FM ratio) reached 15.62, with an outstanding target-to-background ratio explaining the superior efficacy and safety of everolizumab. Furthermore, in vitro distribution studies confirmed that the retention levels of this antibody in non-target organs such as the liver and blood were significantly lower than those in tumor tissues, suggesting favorable pharmacokinetic properties that may reduce associated potential toxicity risks. Histopathological analysis (H\\&E staining) demonstrated no signs of inflammation, necrosis, or other pathological damage in major organs (including the heart, liver, spleen, and kidneys), indicating that evolocimab exhibits good biocompatibility and tolerable safety characteristics.",[28],[331,332,333,334],"esophagus cancer","PET","Ivonescimab","PD-1","2026-02-23",{"date":337,"type":36},"2026-02-27",{"date":339,"type":21},"2026-02-01",{"date":110,"type":21},{"name":342,"class":43},"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University",{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":4,"eligibilityCriteria":349,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":350,"enrollmentInfo":351,"targetDuration":4,"studyType":22,"phases":353,"briefSummary":354,"conditions":355,"keywords":426,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":44},"100432171","virtual-reality-for-gi-cancer-pain-to-improve-patient-reported-outcomes-100432171","NCT04907643","Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes","Randomized Controlled Trial of Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes","Inclusion Criteria:\n\n* Have a primary malignancy of the biliary tract, colon, liver, pancreas, peritoneum, rectum, small intestine, or stomach, with no plan for resection during the study period\n* Tumor types including, but not limited to, adenocarcinoma, squamous cell carcinoma, neuroendocrine tumors, and tumors of mesenchymal origin will be eligible\n* Have clinically significant visceral pain, measured using the standardized NIH PROMIS GI Pain Scale defined as scoring at least 5 points above the nationally normed score\n* Ability to read and write in English\n\nExclusion Criteria:\n\n* Have a condition that interferes with VR usage, including but not limited to seizures, facial injury precluding safe placement of headset, and visual impairments\n* Have cognitive impairment that affects protocol participation. This will be done with a three part cognitive assessment during the initial phone call to assess eligibility followed by consent discussion if eligible.\n* Have brain metastases\n* Have a prognosis of \\\u003C3 months from the time of enrollment per treating oncologist","99 Years",{"count":352,"type":21},360,[24],"Patients with digestive tract malignancy often experience severe and unremitting abdominal pain that negatively affects physical, emotional, and social function, as well as health related quality of life (HRQOL). Therapeutic virtual reality (VR) has emerged as a promising and evidence-based treatment modality for cancer pain. Users of VR wear a pair of goggles with a close-proximity screen in front of the eyes that creates a sensation of being transported into lifelike, three-dimensional worlds. To date, VR has been limited to short-term clinical trials for cancer pain. Moreover, limited research exists on theory-based VR modalities beyond mere distraction, such as VR that employs acceptance and commitment therapy (ACT) with components of biofeedback and mindfulness. To bridge these gaps, this study seeks to: (1) assess the impact of immersive VR on patient-reported outcomes (PROs), including pain, activity metrics, and opioid use among patients with visceral pain from a digestive tract malignancy; (2) assess differences in PROs, activity metrics, and opioid use between skills-based VR therapy vs. distraction VR therapy; and (3) determine patient-level predictors of VR treatment response in visceral cancer pain.\n\nTo address these aims, the study will measure PROs and opioid use in 360 patients randomized among 3 groups and follow them for 60 days after enrollment: (1) an enhanced VR group receiving skills-based VR; (2) a distraction-based VR group receiving patient-selected VR videos; and (3) a VR sham control group using a VR headset with 2-D content. The results will inform best practices for the implementation of VR for visceral cancer pain management and guide selection of patient-tailored experiences.",[356,357,358,359,360,100,306,101,361,178,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,249,383,384,385,386,387,388,389,390,391,392,29,31,393,394,395,396,397,398,399,400,401,402,403,404,405,406,407,408,409,410,28,411,412,413,414,415,416,417,418,419,102,420,421,422,423,424,425],"Cancer Pain","Visceral Pain","Gastrointestinal Neoplasms","Cancer of Gastrointestinal Tract","Small Intestine Cancer","Biliary Tract Cancer","Rectum Cancer","Peritoneal Cancer","Gastrointestinal Cancer Metastatic","Gastrointestinal Cancers - Anus","Gastrointestinal Cancers - Stomach","Gastrointestinal Cancers - Colorectal","Gastrointestinal Cancers - Small Intestine","Small Intestine Cancer Stage III","Small Intestine Cancer Stage IV","Small Intestine Cancer, Recurrent","Pancreas Cancer, Stage III","Pancreas Cancer, Stage IV","Pancreas Cancer, Metastatic","Pancreas Cancer, Recurrent","Liver Cancer Stage IIIa","Liver Cancer Stage IIIb","Liver Cancer Stage IIIc","Liver Cancer Stage IV","Colon Cancer Stage III","Colon Cancer Stage IV","Stomach Cancer Stage III","Stomach Cancer Recurrent","Rectum Cancer, Recurrent","Gastrointestinal Cancers - Liver","Anal Cancer","Anal Cancer Stage III","Anal Cancer Stage IV","Anal Cancer Recurrent","Anal Cancer Metastatic","Anal Cancer, Stage IIIA","Anal Cancer, Stage IIIB","Bile Duct Cancer","Bile Duct Cancer Stage III","Bile Duct Cancer Stage IV","Bile Duct Cancer Stage IVA","Bile Duct Cancer Stage IVB","Bile Duct Cancer Recurrent","Carcinoid Tumor","Carcinoid Tumor of Pancreas","Carcinoid Tumor of Large Intestine","Carcinoid Tumor of GI System","Carcinoid Tumor of Colon","Carcinoid Tumor of Liver","Carcinoid Tumor of Cecum","Carcinoid Tumor of Ileum","Carcinoid Tumor of Rectum","Carcinoid Tumor of the Small Bowel","Carcinoid Tumor of the Stomach","Large Intestine Cancer","Esophagus Cancer, Stage III","Esophagus Cancer, Stage IV","Esophagus Cancer, Recurrent","Gallbladder Cancer","Gallbladder Cancer Stage III","Gallbladder Cancer Stage IV","Gastric (Stomach) Cancer","Neuroendocrine Tumor","Peritoneum Cancer","Esophagus Cancer, Stage I","Esophagus Cancer, Stage II","Gallbladder Cancer Stage I","Gallbladder Cancer Stage II","Bile Duct Cancer Stage I","Bile Duct Cancer Stage II",[427,428,429,430,431],"Virtual Reality","VR","support","GI cancer","cancer pain","2026-02-18",{"date":434,"type":36},"2026-02-20",{"date":436,"type":36},"2021-10-05",{"date":438,"type":21},"2027-03-16",{"name":440,"class":43},"Cedars-Sinai Medical Center",{"id":442,"slug":443,"hasResults":12,"nctId":444,"briefTitle":445,"officialTitle":446,"acronym":4,"eligibilityCriteria":447,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":448,"targetDuration":4,"studyType":22,"phases":450,"briefSummary":452,"conditions":453,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":465,"locationsCount":467},"100425577","phase-3-chemoradiotherapy-in-esophageal-or-esophagogastric-junction-cancer-100425577","NCT04821778","Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer","Cohort Study of Definitive Chemoradiotherapy for Esophageal or Esophagogastric Junction Cancer","Inclusion Criteria:\n\n* ≥18 years；\n* Esophageal or Esophagogastric cancer；\n* Histologically proven squamous cell carcinoma or adenocarcinoma in patients staged as I-IVa(AJCC 8th)；\n* Primary treatment performed in Cancer Hospital, Chinese Academy of Medical Sciences；\n* ECOG PS score: 0\\~1；\n* Estimated survival time ≥3 months；\n* Normal organ and marrow function as defined below:Hemoglobin: greater than or equal to 100g\u002FL ;Leukocytes: greater than or equal to 4,000 G\u002FL; Neutrophil: greater than or equal to 2,000 G\u002FL; Platelets: greater than or equal to 100,000\u002Fmm3 ; Creatinine: less than or equal to 1.5 times the upper limit or CCR greater than or equal to 60 ml\u002Fmin; AST\u002FALT: less than or equal to 2.5 times the upper limit; Total bilirubin: less than or equal to 1.5 times the upper limit; INR: less than or equal to 1.5 times the upper limit; APTT: less than or equal to 1.5 times the upper limit; PT: less than or equal to 1.5 times the upper limit；\n* Informed consent；\n\nExclusion Criteria:\n\n* With any distant metastasis out of regional lymphatic drainage or in liver, lung, bone, CNS, etc；\n* Patients with other cancer history in 5 years except cervical carcinoma in situ and non-malignant melanoma skin cancer；\n* Existing active infection such as active tuberculosis and hepatitis；\n* History of myocardial infarction within the past 6 months or history of ventricular arrhythmia；\n* Uncontrolled illness including, but not limited to, active infection, symptomatic heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness History of allergic reactions attributed to paclitaxel, albumin or cisplatin；\n* Participation in other clinical trials currently or within 4 weeks of selection；\n* Pregnant or lactating females；\n* Absence of medical records.",{"count":449,"type":21},2000,[451],"PHASE3","Definitive chemoradiotherapy is the standard of care in unresectable esophageal or esophagogastric cancer. A multidisciplinary approach, including chemotherapy and radiotherapy, is important for these patients. Morerover, molecular targeting agents does not show clear efficacy in EC up to now. Nowadays, the pace of development of cancer immunotherapies is accelerating. Clinical evidence of the efficacy of immune checkpoint inhibitors and adoptive immunotherapies herald the onset of a new era in cancer immunotherapy. There have also been recent developments to provide a promising frontier in extending the use of immunotherpay or targeting agents to radiotherapy. The purpose of this study was to explore the optimal treatment modalities including PD-1\u002FPD-L1 antibody or targeted drug for patients with unresectable esophageal or esophagogastric junction cancer.",[28,454,455,456,254,457],"Esophagogastric Junction Cancer","Chemoradiation","Targeted Therapy","Chemotherapy Effect","2026-01-18",{"date":460,"type":36},"2026-01-21",{"date":462,"type":36},"2002-01-01",{"date":464,"type":21},"2030-12-31",{"name":466,"class":43},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",5,{"id":469,"slug":470,"hasResults":12,"nctId":471,"briefTitle":472,"officialTitle":473,"acronym":4,"eligibilityCriteria":474,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":475,"enrollmentInfo":476,"targetDuration":4,"studyType":22,"phases":478,"briefSummary":479,"conditions":480,"keywords":488,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":44},"100571099","target-specific-immunopet-imaging-of-digestive-system-carcinoma-100571099","NCT06715839","Target-specific immunoPET Imaging of Digestive System Carcinoma","Development and Clinical Translation of immunoPET Imaging Probes for Digestive System Carcinoma","Inclusion Criteria:\n\n1. Aged 18-75 years old and of either sex；\n2. Histologically confirmed diagnosis of digestive system carcinoma or suspected digestive system carcinoma by diagnostic imaging;\n3. Capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol.\n\nExclusion Criteria:\n\n1. Pregnancy；\n2. Severe hepatic and renal insufficiency;\n3. History of serious surgery in the last month;\n4. Allergic to antibody or single-domain antibody radiopharmaceuticals.","75 Years",{"count":477,"type":21},400,[24],"The aim of this study is to establish and optimize the target-specific PET\u002FCT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in digestive system malignant tumors will be evaluated.",[481,482,483,484,485,306,178,101,362,297,28,486,360,29,487],"Malignancy","Digestive Cancer","Digestive System Neoplasm","Digestive System Carcinoma","Digestive System Cancer","Gallbladder Carcinoma","Bile Duct Carcinoma",[489,490,491,492,493],"human epidermal growth factor receptor 2 (HER2)","Trophoblast cell surface antigen 2 (TROP2)","Glypican-3 (GPC3)","Glycoprotein A33 (gpA33)","Nectin cell adhesion molecule-4 (Nectin-4)","2025-12-25",{"date":496,"type":36},"2025-12-31",{"date":498,"type":36},"2024-12-04",{"date":500,"type":21},"2027-09",{"name":502,"class":43},"RenJi Hospital",{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":4,"eligibilityCriteria":509,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":475,"enrollmentInfo":510,"targetDuration":4,"studyType":22,"phases":512,"briefSummary":513,"conditions":514,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":522,"locationsCount":44},"100574012","phase-1-a-trial-of-the-combination-of-afatinib-and-palbociclib-in-previously-treated-advanced-esophageal-squamous-cell-carcinoma-100574012","NCT06753747","A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma","A Phase 1b\u002F2 Trial of Afatinib Plus Palbociclib in Previously Treated Recurrent or Metastatic Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n* Age between 18 and 75 years\n* Histologically or cytologically confirmed as ESCC, locally advanced and unresectable, with local recurrence (local lymph node metastases) or distant metastases\n* Immunohistochemistry confirmed EGFR(3+) or EGFR-FISH-amplification or next generation sequencing confirmed EGFR-amplification (EGFR expression is not required in Phase 1b, but only patients with EGFR overexpression will be included in Phase 2).\n* Disease progression after first-line or subsequent lines of therapy.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Adequate organ function within 7 days prior to treatment initiation, meeting the following criteria:Hematology (without transfusion, blood products, or administration of G-CSF or other hematopoietic stimulants within the past 14 days):\n\n  1. Hemoglobin (Hb) ≥ 90 g\u002FL;\n  2. Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL;\n  3. Platelet count (PLT) ≥ 75 × 10⁹\u002FL.\n\nSerum biochemistry:\n\n1. Total bilirubin (TBIL) ≤ 1.5 × the upper limit of normal (ULN);\n2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; for patients with liver metastases, ALT and AST ≤ 5 × ULN;\n3. Serum creatinine (Cr) ≤ 1.5 × ULN or creatinine clearance (CCr) ≥ 60 mL\u002Fmin. Cardiac function: Left ventricular ejection fraction (LVEF) ≥ 50%, as assessed by Doppler ultrasound.\n\nCoagulation: International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN.\n\n* Female patients of childbearing potential must agree to use appropriate contraception from screening until 3 months after the end of treatment and must not be breastfeeding. A negative pregnancy test is required within 7 days before the start of treatment. Male patients must agree to use appropriate contraception or have undergone surgical sterilization during the study and for 8 weeks after the last administration of study medication.\n* All subjects are recruited on a voluntary basis and sign the informed consent. They are required to be compliant with the study and cooperative with the follow-up.\n\nExclusion Criteria:\n\n* Patients who have a history of other malignancies in the past five years (except for the cured basal cell carcinoma and cervical carcinoma in situ)\n* The patient has any active autoimmune disease or a history of autoimmune disease\n* History of severe allergic reactions or known allergies to macromolecular protein preparations, Afatinib, Palbociclib, or any component of their formulations that have resulted in hospitalization.\n* Presence of contraindications to Palbociclib or Afatinib.\n* Previous or planned treatments as follows:\n\n  1. Prior use of EGFR inhibitors or CDK4\u002F6 inhibitors.\n  2. Administration of any live vaccines (e.g., influenza or varicella vaccines) within 4 weeks before the first dose or during the study.\n  3. Major surgery or significant trauma within 4 weeks before the first dose.\n  4. Residual toxicities from prior anti-tumor therapies not resolved to ≤ Grade 1 per CTCAE v5.0, except for alopecia or platinum-based therapy-induced neuropathy.\n* Severe medical conditions, such as:\n\n  1. NYHA Class II or higher heart failure.\n  2. Ischemic heart disease (e.g., myocardial infarction or angina).\n  3. Clinically significant supraventricular or ventricular arrhythmias.\n  4. Poorly controlled diabetes (fasting blood glucose ≥ 10 mmol\u002FL).\n  5. Poorly controlled hypertension (systolic BP \\> 150 mmHg and\u002For diastolic BP \\> 100 mmHg).\n  6. Left ventricular ejection fraction (LVEF) \\\u003C 50% on echocardiography.\n  7. QTc interval \\> 450 ms in males or \\> 470 ms in females.\n  8. Abnormal ECG findings deemed to pose additional risk by the investigator.\n* Active infections or unexplained fever within 48 hours prior to the first dose, or systemic antibiotic use within one week prior to informed consent.\n* Active hepatitis B (HBV DNA ≥ 2000 IU\u002FmL or ≥ 10⁴ copies\u002FmL), hepatitis C (anti-HCV antibody positive with detectable HCV RNA), known HIV positivity, or acquired immunodeficiency syndrome (AIDS).\n* Any medical or other condition which, in the opinion of the investigator, would preclude participation in a clinical trial.\n* Pregnancy or lactation.\n* Receipt of any investigational drug within 4 weeks before the first dose or concurrent enrollment in another clinical trial, except for observational (non-interventional) studies or interventional trials in follow-up.\n* Any other factors deemed by the investigator to potentially interfere with study participation, including the ability to complete study treatment and follow-up.",{"count":511,"type":21},45,[143,75],"The goal of this clinical trial is to learn if Afatinib plus Palbociclib works in previously treated recurrent or metastatic esophageal squamous cell carcinoma. It will also learn about the safety of the combination of Afatinib and Palbociclib. The main questions it aims to answer are:\n\nWhat is the safe and tolerable dose of Afatinib when combined with 100 mg of Palbociclib (administered orally, three weeks on and one week off)?\n\nDoes the combination therapy of Afatinib and Palbociclib induce a tumor response in patients with recurrent or metastatic esophageal squamous cell carcinoma who have received prior treatments?",[28],"2025-11-25",{"date":517,"type":36},"2025-12-03",{"date":519,"type":36},"2025-09-10",{"date":521,"type":21},"2028-09",{"name":523,"class":43},"West China Hospital",{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":530,"eligibilityCriteria":531,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":532,"targetDuration":4,"studyType":22,"phases":534,"briefSummary":535,"conditions":536,"keywords":537,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":545,"locationsCount":467},"100504576","acupuncture-for-oxaliplatin-induced-peripheral-neuropathy-in-gastro-intestinal-cancer-patients-100504576","NCT05850130","Acupuncture for Oxaliplatin-induced Peripheral Neuropathy in Gastro-intestinal Cancer Patients","A Multicenter, 2-cohort Phase II GERCOR Study to Evaluate the Interest of Acupuncture on Oxaliplatin-induced Peripheral Neuropathy in Patients With Gastro-intestinal Solid Tumors Who Discontinued Oxaliplatin-based Chemotherapy (ACUPOX)","ACUPOX","Inclusion Criteria\n\nPatient is included if:\n\n1. Agree to participate in this study, voluntarily signing a written informed consent form,\n2. Aged ≥ 18 years,\n3. Have an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-2,\n4. Have histologically or cytologically confirmed gastro-intestinal solid tumors, previously treated with any oxaliplatin-based chemotherapy; a concomitant radio-chemotherapy course is allowed,\n5. Had the last oxaliplatin infusion \\> 2 weeks before inclusion,\n6. Present OIPN with a numerical rating score (NRS) ≥ 4\u002F10 at inclusion,\n7. Currently receiving or recently completed chemotherapy (adjuvant, neoadjuvant, or advanced stage). Patients may receive current chemotherapy treatment (e.g., with FOLFIRI, 5-fluorouracil, bevacizumab regimens), excluding platinum salts and taxane-based regimens during the study,\n8. Are able to understand\u002Fread French,\n9. Are registered in a national health care system (PUMa - Protection Universelle Maladie included),\n\nExclusion Criteria\n\nPatients is excluded if:\n\n1. Had acupuncture sessions for the prevention of chemotherapy-induced side effects in the last 3 months prior to inclusion,\n2. Had previous and\u002For current chemotherapy treatments with taxane-based regimens (e.g., the TFOX regimen \\[docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil\\]),\n3. Have a history of preexisting clinically-significant peripheral neuropathy due to any cause other than chemotherapy (borrelia infection, human immunodeficiency virus infection, hereditary factors, tumor compression, nutritional deprivation, alcohol, diabetes, etc.),\n4. Have a recent history (within 4 weeks prior to start of acupuncture) of abusing alcohol, prescription, or illicit drugs (including cannabinoid), or medical, psychological, or social conditions that may interfere with the patient's compliance with the study intervention, NB: The patient should be informed that drinking alcohol should be avoided while on study.\n5. Have any other condition that, in the opinion of the investigator, is unstable or could jeopardize the safety of the patient and her\u002Fhis compliance during the study,\n6. Have limb edema of grade 3 (CTCAE v5),\n7. Had phytotherapy within 2 weeks before a week 1-14 intervention,\n8. Are pregnant or breastfeeding,\n9. Are under the tutorship or guardianship of the state or in custody of the justice system.",{"count":533,"type":21},182,[24],"ACUPOX is a multicenter, open label, 2-cohort based phase II clinical study evaluating the interest of a standardized protocol of verum acupuncture in treatment of Oxaliplatin-induced peripheral neuropathy in patients with gastro-intestinal solid tumors who discontinued oxaliplatin-containing chemotherapy.",[27,306,176,100,28],[538],"acupuncture","2025-07-22",{"date":541,"type":36},"2025-07-23",{"date":543,"type":36},"2023-11-22",{"date":40,"type":21},{"name":546,"class":43},"GERCOR - Multidisciplinary Oncology Cooperative Group",{"id":548,"slug":549,"hasResults":12,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":4,"eligibilityCriteria":553,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":475,"enrollmentInfo":554,"targetDuration":4,"studyType":22,"phases":556,"briefSummary":557,"conditions":558,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":560,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":565,"locationsCount":4},"100596496","phase-2-tislelizumab-combined-with-chemotherapy-for-resectable-esophageal-squamous-cell-carcinoma-followed-by-crt-or-surgery-100596496","NCT07046221","Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery","Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery: A Prospective, Open-label, Multicenter Clinical Study","Inclusion Criteria:\n\n* The subjects were included in this study and signed the informed consent form.\n* Male or female patients aged between 18 and 75 years old;\n* Patients diagnosed with esophageal squamous cell carcinoma by histopathology;\n* According to the 8th edition of the AJCC Esophageal cancer TNM staging system, it is located in cT2N+ or cT3-4aNanyM0 (confirmed by enhanced CT\u002FMRI of the chest and abdomen), and the lesion is located in the thoracic segment.\n* ECOG score: 0-1.\n* The main organs function normally, that is, they meet the following standards:\n\n  1. Blood routine (no blood transfusion was performed within 14 days before treatment, no granulocyte colony-stimulating factor \\[G-CSF\\] was used, and no other drugs were used for correction);\n\n     The absolute neutrophil count (ANC) was ≥1.5×109\u002FL;\n\n     Hemoglobin (HB) ≥9.0 g\u002FdL;\n\n     Platelet count (PLT) ≥100×109\u002FL;\n  2. Blood biochemistry\n\nCreatinine clearance rate ≥60 mL\u002Fmin;\n\nTotal bilirubin (TBIL) ≤ 1.5×ULN;\n\nAspartate aminotransferase (AST) or alanine aminotransferase (ALT) level ≤2.5×ULN;\n\n* The expected survival period is ≥3 months;\n* Female subjects with reproductive capacity and male subjects whose partners are of childbearing age need to adopt a medically approved contraceptive measure during the study treatment period and for at least 3 months after the last treatment\n\nExclusion Criteria:\n\n* There are clinically uncontrolled pleural effusions, pericardial effusions or ascites that require repeated drainage or medical intervention (within 2 weeks before randomization);\n* It is known that there is intolerance or resistance to the chemotherapy specified in the trial protocol;\n* Have received any other ESCC anti-tumor treatments (e.g., targeted treatments for PD-1, PD-L1, PD-L2, or other tumor immunotherapy, radiotherapy, targeted therapy, ablation, or other systemic or local anti-tumor treatments);\n* Patients with active autoimmune diseases or a history of autoimmune diseases that may recur, or a known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;\n* Have a history of interstitial lung disease, non-infectious pneumonia or uncontrolled systemic diseases, including pulmonary fibrosis, acute lung diseases, etc.\n* Before enrollment, there was a severe chronic or active infection (including tuberculosis infection, etc.) that required systemic antibacterial, antifungal or antiviral treatment;\n* A known history of HIV infection;\n* Having suffered from other malignant tumors within the past five years (excluding cured basal cell carcinoma of the skin, carcinoma in situ of the breast and carcinoma in situ of the cervix);\n* Have received live vaccines within 28 days before enrollment;\n* Participated in other therapeutic clinical trials within 4 weeks;\n* Those that the researchers consider unsuitable for inclusion.\n* Distant metastasis exists (except for supraclavicular lymph nodes).",{"count":555,"type":21},60,[75],"To explore the non-inferiority of the 2y-OS rate of tislelizumab combined with chemotherapy after sequential CRT in the treatment of resectable esophageal squamous cell carcinoma compared with the surgical group",[28],"2025-07-16",{"date":561,"type":36},"2025-07-20",{"date":563,"type":21},"2025-08-01",{"date":316,"type":21},{"name":566,"class":567},"Fujian Cancer Hospital","OTHER_GOV",{"id":569,"slug":570,"hasResults":12,"nctId":571,"briefTitle":572,"officialTitle":573,"acronym":4,"eligibilityCriteria":574,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":475,"enrollmentInfo":575,"targetDuration":4,"studyType":22,"phases":577,"briefSummary":578,"conditions":579,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":580,"lastUpdatePostDateStruct":581,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":4},"100594418","phase-2-tislelizumab-combined-with-chemotherapy-for-the-perioperative-treatment-of-esophageal-squamous-carcinoma-100594418","NCT07019181","Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma","Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma： Single-arm Clinical Phase II Study","Inclusion Criteria:\n\n* Subjects were enrolled in the study and signed an informed consent form.\n* Male or female patients between the ages of 18 and 75.\n* Patients with esophageal squamous carcinoma diagnosed by histopathology.\n* According to the TNM staging system of esophageal cancer in the 8th edition of the AJCC,the disease is in the stage of cT3-4aN0M0 or cT1b-4aN+M0 (confirmed by thoracic and abdominal enhancement CT\u002FMRI), and the lesion is located in the thoracic segment.\n* ECOG score: 0-1.\n* Normal functioning of major organs, i.e. meeting the following criteria.\n\n  1. Blood count (no blood transfusions, granulocyte colony-stimulating factor \\[G-CSF\\], or other medications corrected within 14 days prior to treatment); and Absolute neutrophil count (ANC) ≥1.5×109\u002FL; hemoglobin (HB) ≥9.0 g\u002FdL; and Platelet count (PLT) ≥ 100 x 109\u002FL;\n  2. blood biochemistry Creatinine clearance ≥60 mL\u002Fmin. Total bilirubin (TBIL) ≤ 1.5 x ULN. Albuminous aminotransferase (AST) or albuminous aminotransferase (ALT) levels ≤ 2.5 x ULN;\n* Expected survival \\> 6 months.\n* Female subjects of childbearing potential and male subjects with partners of childbearing potential are required to use a medically approved contraceptive method during study treatment and for at least 6 months after the last treatment.\n\nExclusion Criteria:\n\n* The presence of clinically uncontrolled chest that required repeated drainage or medical intervention (within 2 weeks prior to randomization) Hydrocele, pericardial hydrocele or ascites;\n* Known intolerance or resistance to chemotherapy specified in the trial protocol;\n* Have received any other ESCC anti-tumor therapy (e.g., targeting PD-1, PD-L1, PD-L2) Or other tumor immunotherapy, radiotherapy, targeted therapy, ablation, or other systemic or local anti-tumor therapy);\n* Patients who have an active autoimmune disease or have a history of an autoimmune disease but may relapse may have a known abnormality History of body organ transplantation or allogeneic hematopoietic stem cell transplantation;\n* A history of interstitial lung disease, non-infectious pneumonia, or uncontrolled systemic disease, including pulmonary fibrosis, Acute lung disease;\n* There were severe chronic or active patients requiring systemic antimicrobial therapy, antifungal therapy or antiviral therapy before enrollment Infection (including tuberculosis infection, etc.);\n* Have a known history of HIV infection;\n* The presence of any serious or uncontrolled systemic disease, including but not limited to:\n\nUnstable angina pectoris, congestive heart failure, New York Heart Association (NYHA) grade ≥ 2 chronic heart failure; Any arterial thrombosis, embolism, or ischemia, such as myocardial infarction, cerebrovascular accident, or transient ischemic attack, during the 6 months prior to the first dose of the study; Uncontrolled hypertension (i.e., ≥ CTC-AE level 2 hypertension after medication); active pulmonary tuberculosis; those who have a history of psychotropic substance abuse and cannot abstain or have mental disorders;\n\n* Had other malignancies in the past 5 years (cured skin basal cell carcinoma, breast carcinoma in situ and Except primary cervical cancer);\n* Had received live vaccine within 28 days prior to enrollment;\n* Have participated in other therapeutic clinical trials within 4 weeks;\n* And those deemed unsuitable for inclusion by the researchers.",{"count":576,"type":21},26,[75],"Evaluating the rate of pathologic complete remission in patients with squamous esophageal cancer treated perioperatively with tislelizumab in combination with chemotherapy",[28],"2025-06-12",{"date":582,"type":36},"2025-06-13",{"date":584,"type":21},"2025-07-30",{"date":586,"type":21},"2026-12-31",{"name":588,"class":43},"The First Affiliated Hospital of Xiamen University",{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":4,"eligibilityCriteria":595,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":475,"enrollmentInfo":596,"targetDuration":4,"studyType":22,"phases":598,"briefSummary":599,"conditions":600,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":602,"startDateStruct":604,"completionDateStruct":606,"leadSponsor":608,"locationsCount":4},"100569286","phase-2-tislelizumab-as-single-agent-neoadjuvant-immunotherapy-in-resectable-esophageal-squamous-cell-carcinoma-100569286","NCT06692270","Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma","Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma: A Single-Arm, Phase II Clinical Study（TISNEOS）","Inclusion Criteria:\n\n* 18 years old ≤75 years old, male or female;\n* T2-3N0-+M0 or T1bN+M0 thoracic esophageal squamous cell carcinoma (as defined in AJCC 8th Edition) with a definite gastroscopic biopsy.\n* There is at least one measurable lesion (RECIST1.1 standard);\n* ECOG PS 0\\~1;\n* Expected survival ≥ 12 months;\n* Newly diagnosed patients who have not received surgery, chemoradiotherapy, targeted therapy, immunotherapy and other treatments before;\n* Women of childbearing age must have a negative pregnancy test (serum or urine) within 14 days prior to enrollment. Male subjects and women of reproductive age must be on contraception within 24 weeks of starting the first study drug and the last study drug.\n* The laboratory test value of the patient before medication shall meet the following criteria:\n\n  1. Blood routine: WBC≥3.0 × 109\u002FL; ANC≥1.5 × 109\u002FL; PLT≥100 × 109\u002FL; HGB≥ 9.0g \u002FdL\n  2. Liver function: AST≤2.5 × ULN, ALT≤2.5 × ULN, TBIL≤1.5 × ULN\n  3. Renal function: Cr≤1.5 × ULN or CrCl ≥50 mL\u002Fmin\n  4. Coagulation function: INR≤1.5, APTT≤1.5 ×ULN;\n* Subjects voluntarily joined the study, signed informed consent, had good compliance, and cooperated with follow-up.\n\nExclusion Criteria:\n\n* Esophageal adenocarcinoma was confirmed by histological or cytological pathology;\n* Previous T cell co-stimulation or immune checkpoint therapy, including but not limited to CTLA-4 inhibitors, PD-1 inhibitors, PD-L1\u002F2 inhibitors, or other T cell-targeting drugs;\n* A previous or current history of cancer other than esophageal cancer, other than non-melanoma skin cancer that has been treated therapeutically, cervical cancer in situ, or other cancer that has been treated therapeutically and has not shown signs of recurrence for at least 5 years;\n* Interstitial lung disease, drug-induced pneumonia, radiation pneumonia requiring steroid treatment or active pneumonia with clinical symptoms or severe lung dysfunction;\n* Uncontrolled hypertension with standard treatment (blood pressure not stabilized below \\\u003C 150\u002F90 mmHg);\n* Hereditary bleeding tendency or coagulation dysfunction. There were clinically significant bleeding symptoms or definite bleeding tendencies within 3 months prior to enrollment, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, stool occult blood ++ or above at baseline;\n* Have clinical symptoms or diseases of heart that are not well controlled, such as: (1) NYHA2 or higher heart failure, (2) unstable angina pectoris, (3) myocardial infarction within 24 weeks, (4) clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention;\n* Severe infections (CTCAE \\> Class 2), such as severe pneumonia requiring hospitalization, bacteremia, and infection complications, occurred within 4 weeks prior to the first use of the study drug;\n* Patients with clinically uncontrollable third space effusion (such as pleural effusion\u002Fpericardial effusion, who do not need to drain the effusion or have no significant increase in effusion after 3 days of stopping drainage can be included in the group);\n* Imaging (CT or MRI) shows that the tumor has invaded the major blood vessels, or the investigator determines that the tumor is highly likely to invade important blood vessels and cause fatal massive bleeding during the follow-up study;\n* A history of immunodeficiency, including HIV testing positive, or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation and allogeneic bone marrow transplantation;\n* Patients with active hepatitis B (defined as positive HBV surface antigen \\[HBsAg\\] test result during screening and HBV-DNA test value higher than the upper limit of normal value in the laboratory of the research center) or hepatitis C (defined as positive HCV surface antibody \\[HCsAb\\] test result during screening and HCV-RNA positive);\n* Those who have allergic reaction to the experimental drug used in this application;\n* According to the investigator's judgment, the subjects have other factors that may lead to the forced termination of the study.",{"count":597,"type":21},20,[75],"Tislelizumab in resectable esophageal squamous cell carcinoma",[28],"2025-02-26",{"date":603,"type":36},"2025-02-28",{"date":605,"type":21},"2025-05-15",{"date":607,"type":21},"2027-01-10",{"name":566,"class":567},{"id":610,"slug":611,"hasResults":12,"nctId":612,"briefTitle":613,"officialTitle":614,"acronym":615,"eligibilityCriteria":616,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":475,"enrollmentInfo":617,"targetDuration":4,"studyType":22,"phases":619,"briefSummary":620,"conditions":621,"keywords":622,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":625,"lastUpdatePostDateStruct":626,"startDateStruct":628,"completionDateStruct":630,"leadSponsor":631,"locationsCount":263},"100283653","chemoradiation-versus-esophagectomy-for-locally-advanced-esophageal-cancer-100283653","NCT02972372","Chemoradiation Versus Esophagectomy for Locally Advanced Esophageal Cancer","A Randomized, Open-label, Multicenter Trial of the Chemoradiation Versus Standard Esophagectomy for Locally Advanced Resectable Esophageal Squamous Cell Cancer in Chinese Patients","CELAEC","Inclusion Criteria:\n\n* Chinese\n* esophageal squamous cell cancer\n* mid or lower esophageal cancer\n* tumor is resectable disease\n* clinical stage: cT1bN+Mo, or cT2-4aN0-2M0\n\nExclusion Criteria:\n\n* who had distant metastasis to solid visceral organs or local invasion into trachea, descending aorta, or recurrent laryngeal nerve.\n* who had a serious premorbid condition or a poor physical status that compromised a thoracotomy.",{"count":618,"type":21},196,[24],"The aim of this study is to compare outcomes in Chinese patients with locally advanced resectable esophageal squamous cell cancer who have received either surgery or definitive chemoradiation (CRT) by the randomized, open-label, multicenter trial.",[28],[252,623,624],"chemoradiation","esophagectomy","2025-02-06",{"date":627,"type":36},"2025-02-10",{"date":629,"type":36},"2016-11",{"date":40,"type":21},{"name":632,"class":43},"The First Affiliated Hospital of Henan University of Science and Technology",{"id":634,"slug":635,"hasResults":12,"nctId":636,"briefTitle":637,"officialTitle":638,"acronym":639,"eligibilityCriteria":640,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":475,"enrollmentInfo":641,"targetDuration":4,"studyType":22,"phases":643,"briefSummary":644,"conditions":645,"keywords":646,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":650,"lastUpdatePostDateStruct":651,"startDateStruct":653,"completionDateStruct":655,"leadSponsor":656,"locationsCount":44},"100549180","phase-2-neoadjuvant-comprehensive-treatment-for-unresectable-esophageal-cancer-100549180","NCT06430658","Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer","NEoadjuvant Total RX for Borderline Unresectable Esophageal Squamous Cell Carcinoma: a Prospective Randomized, Three-Arm, Open-Label Phase II Trial (NEXUS-2)","NEXUS-2","Inclusion Criteria:\n\n1. Histologically confirmed sorely ESCC without other histology subtypes.\n2. Thoracic esophageal cancer.\n3. No prior anti-cancer treatment, including but not limited to surgery, radiotherapy, chemotherapy, targeted therapy, or immunotherapy.\n4. Borderline unresectable locally advanced ESCC deemed by investigators as suspicious of but not confirmed T4b according to the American Joint Committee on Cancer (AJCC) 8th edition staging classification or extracapsular lymph node involvement (ELNI).\n5. The Karnofsky Performance Scale (KPS) ≥70.\n6. Normal primary organ functions, including but not limited to hemoglobin (Hb) ≥ 100g\u002FL; white blood cell (WBC) ≥ 3.5×10\\*9\u002FL; neutrophil count (NEUT) ≥ 1.5×10\\*9\u002FL; platelets (PLT) ≥ 100×10\\*9\u002FL; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 1.5×UNL; total bilirubin (TBIL) ≤ 1.5×UNL; creatinine ≤ 1.5UNL; blood urea nitrogen (BUN) ≤ 1.0×UNL.\n\nExclusion Criteria:\n\n1. Synchronous and metachronous primary malignancies in but not limited to the upper aerodigestive tract, except for cured basal cell carcinoma of the skin and carcinoma in situ of the cervix.\n2. Patients have undergone any type of anti-cancer treatment.\n3. Baseline clinical stage M1 per AJCC 8th edition of staging classification, including supraclavicular lymph node metastases.\n4. Investigators assessed major vessel involvement with high-risk hemorrhage.\n5. A higher probability of esophageal perforation during conversion therapy.\n6. Active infectious diseases, including but not limited to tuberculosis, hepatitis B virus, or hepatitis C virus.\n7. Allergic to anti-cancer agents, including but not limited to anti-PD-1 or chemotherapy agents.\n8. Given cardiopulmonary dysfunction, patients can not tolerate conversion therapy or surgery.\n9. Pregnant or lactating women and women of childbearing potential who lacked effective contraception.\n10. Non-compliance with the inclusion criteria judged by investigators.",{"count":642,"type":21},90,[75],"Patients diagnosed with locally advanced esophageal squamous cell carcinoma (ESCC) that is deemed unresectable face a bleak prognosis. Recent phase 1\u002F2 studies have demonstrated the efficacy and safety of augmenting neoadjuvant concurrent chemoradiotherapy with immunotherapy in treating resectable ESCC. The present study is a prospective, 3-arm, randomized trial that seeks to evaluate the efficacy of diverse conversion therapy modalities in patients with unresectable ESCC. The study objectives include R0 resection rate, treatment-related adverse events, morbidity and mortality, 1-year progression-free survival (PFS), and 1-year overall survival (OS) rates.\n\nTislelizumab is a humanized IgG4 monoclonal antibody with high affinity\u002Fspecificity for programmed cell death protein 1 (PD-1). Tislelizumab was specifically engineered to minimize binding to FcɤR on macrophages, thereby abrogating antibody-dependent phagocytosis, a potential mechanism of T-cell clearance and resistance to anti-PD-1 therapy.\n\nThis trial will provide valuable insights into the effectiveness of the three conversion therapy modalities and help to inform clinical decision-making for patients with unresectable locally advanced ESCC.",[28],[28,647,648,649],"Chemoradiotherapy","conversion surgery","immunotherapy","2024-12-21",{"date":652,"type":36},"2024-12-27",{"date":654,"type":36},"2024-04-01",{"date":110,"type":21},{"name":466,"class":43},{"id":658,"slug":659,"hasResults":12,"nctId":660,"briefTitle":661,"officialTitle":661,"acronym":662,"eligibilityCriteria":663,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":664,"targetDuration":4,"studyType":121,"phases":4,"briefSummary":666,"conditions":667,"keywords":670,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":676,"lastUpdatePostDateStruct":677,"startDateStruct":679,"completionDateStruct":681,"leadSponsor":683,"locationsCount":44},"100558357","her2-status-in-esophagogastric-adenocarcinoma-and-its-associations-with-patients-clinicopathological-outcomes-100558357","NCT06550063","HER2 Status in Esophagogastric Adenocarcinoma and Its Associations With Patient's Clinicopathological Outcomes","HERA","Inclusion Criteria:\n\n* Patients with newly diagnosed EGA from 2000 to April 2024 across all stages of disease\n* Primary tumour HER2 status tested as routine in all patients with EGA\n* Patients aged 18 years or over\n\nExclusion Criteria:\n\n\\- Patients with esophageal squamous cell carcinoma",{"count":665,"type":21},2188,"Targeted therapies offer promise to improve oncologic outcomes in esophagogastric adenocarcinoma (EGA). The landmark 'Trastuzumab for gastric cancer (ToGA)' trial established the therapeutic value of Human Epidermal Growth Factor Receptor 2 (HER2) directed therapy in advanced gastric and esophagogastric junction adenocarcinoma, setting a standard of care. Further studies, such as DESTINY-gastric01 and DESTINY-gastric02, have demonstrated the efficacy of antibody-drug conjugates (ADCs) targeting HER2-positive gastric and junctional tumours. The use of HER2-directed therapies in the curative intent setting has more recently been evaluated with favourable outcomes in phase II studies. However, data regarding the prevalence and prognostic significance of HER2 overexpression among patients undergoing treatment with curative intent are limited. Furthermore, few studies have evaluated the clinical significance of intratumoural and tumour-metastatic heterogeneity of HER2 expression, and the finding of HER2-low, in this context, which may have important implications for implementation of neoadjuvant targeted therapies in future. While limited single centre series have evaluated the clinicopathologic significance of HER2 status in EGA, no previous international multicentre study of this nature has been reported.\n\nThe goal of this international, multi-center, retrospective observational study is to elucidate the prevalence and clinical significance of HER2 expression in patients with EGA across different regions globally. The study also aims to assess the clinical significance of HER2 heterogeneity in a large, international cohort of patients with EGA, and its association with clinicopathological outcomes in patients with advanced and recurrent disease.",[28,176,668,669],"HER2-positive Cancer","HER2-low Cancer",[671,672,673,674,675],"Esophageal cancer","Gastric cancer","HER2-positive cancer","HER2-low cancer","Targeted treatment","2024-08-12",{"date":678,"type":36},"2024-08-13",{"date":680,"type":21},"2024-08-20",{"date":682,"type":21},"2025-08-31",{"name":684,"class":43},"St. James's Hospital, Ireland",{"id":686,"slug":687,"hasResults":12,"nctId":688,"briefTitle":689,"officialTitle":690,"acronym":691,"eligibilityCriteria":692,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":693,"enrollmentInfo":694,"targetDuration":4,"studyType":22,"phases":695,"briefSummary":696,"conditions":697,"keywords":698,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":703,"lastUpdatePostDateStruct":704,"startDateStruct":706,"completionDateStruct":708,"leadSponsor":710,"locationsCount":711},"100555319","goal-directed-enteral-nutritional-perioperative-management-100555319","NCT06510543","Goal-directed Enteral Nutritional Perioperative Management","Goal-directed Enteral Nutritional Therapy for Malnourished Esophageal Cancer Patients During Perioperative Management","GENTLEMAN","Inclusion Criteria:\n\n1. Aged 18-80 years old;\n2. ECOG PS 0\\~1;\n3. NRS 2002 score ≥3;\n4. Malnutrition diagnosed according to the GLIM criteria;\n5. Histopathologically confirmed as esophageal squamous cell carcinoma;\n6. Primary tumors located in thoracic esophagus;\n7. Resectable locally advanced disease with clinical stage II to IVA (8th edition UICC\u002FAJCC) evaluated by a multidisciplinary team;\n8. Neoadjuvant therapy will be administered, which may entail preoperative chemo-radiotherapy, chemotherapy only, or a combination of immunotherapy such as anti-PD-1\u002FPD-L1;\n9. Informed consent for random assignment and completion of the protocol.\n\nExclusion Criteria:\n\n1. NRS 2002 score \\\u003C 3;\n2. Upfront surgery without neoadjuvant treatment;\n3. Any comorbidity interferes with the digestion and absorption of ORAL IMPACT®;\n4. Receiving any other nutritional support during the study;\n5. Unable to consume nutrition orally or receive it through tube feeding before surgery;\n6. History of other malignancies in the past 5 years, except successfully treated basal-cell skin carcinoma and cervical tumors in situ;\n7. Severe abnormalities of liver and kidney functions (ALT≥2 times the upper limit of normal; Total bilirubin Tbil≥2 upper limit of normal; Creatinine Cr≥2 upper limit of normal);\n8. Metabolic disorders, including uncontrolled diabetes mellitus or fasting blood glucose ≥10mmol\u002FL, hypothyroidism, or hyperthyroidism;\n9. Receiving fat emulsion containing Omega-3 fatty acids, glutamine, thymosin, glucocorticoid, thyroxine, growth hormone, and anti-tumor necrosis factor biologic agents\n10. History of known allergy to any component of ORAL IMPACT®;\n11. Pregnant or lactating women, women of childbearing potential with either a positive pregnancy test at baseline or not using a reliable and appropriate contraceptive method;\n12. Refuse to sign the consent or unable to follow the study protocol;\n13. Inappropriate to participate in this study judged by investigators.","80 Years",{"count":477,"type":21},[24],"This clinical trial aims to determine whether perioperative goal-directed nutritional therapy can prevent postoperative pulmonary and other major complications in malnourished esophageal squamous cell cancer patients. Its main question is whether individualized nutritional therapy can improve short-term surgical outcomes and long-term prognosis. Researchers will compare goal-directed and conventional nutritional therapy to identify differences in morbidities and survival.",[28],[177,204,699,700,701,702],"Nutritional Therapy","Morbidity","Survival","Malnourished","2024-07-14",{"date":705,"type":36},"2024-07-19",{"date":707,"type":36},"2024-03-30",{"date":709,"type":21},"2031-05-30",{"name":466,"class":43},17,{"id":713,"slug":714,"hasResults":12,"nctId":715,"briefTitle":716,"officialTitle":717,"acronym":718,"eligibilityCriteria":719,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":475,"enrollmentInfo":720,"targetDuration":721,"studyType":121,"phases":4,"briefSummary":722,"conditions":723,"keywords":724,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":726,"lastUpdatePostDateStruct":727,"startDateStruct":729,"completionDateStruct":731,"leadSponsor":733,"locationsCount":263},"100545731","multicenter-cohort-study-of-esd-and-chemo-radiotherapy-for-high-risk-early-stage-esophageal-cancer-100545731","NCT06385717","Multicenter Cohort Study of ESD and Chemo-radiotherapy for High-risk Early-stage Esophageal Cancer","Multicenter Cohort Study of Chemo-radiotherapy After Endoscopic Submucosal Dissection for High-risk Early-stage Esophageal Cancer","ESCORT","Inclusion Criteria:\n\n* 1\\. Esophageal cancer patients who are pathologically confirmed as pT1a-MM stage or pT1b stage after endoscopic submucosal dissection； 2. No definite contraindications for chemo-radiotherapy； 3. Informed consent has been signed； 4. Refused surgery after endoscopic submucosal dissection.\n\nExclusion Criteria:\n\n* 1\\. Severe heart, brain, lung disease or renal dysfunction; 2. Previous history of other malignancies; 3. Prior radiation or chemotherapy 4. Researchers consider it inappropriate to participate in this experiment",{"count":73,"type":21},"3 Years","This multicenter, prospective observational cohort study has the potential to optimize individualized chemoradiotherapy regimen for early-stage esophageal cancer patients who have received endoscopic submucosal dissection.",[28],[725],"esophagus cancer; radio-chemotherapy; ESD","2024-04-25",{"date":728,"type":36},"2024-04-26",{"date":730,"type":21},"2024-05-01",{"date":732,"type":21},"2029-01-31",{"name":87,"class":43}]